BML, Inc.

TSE:4694 Stock Report

Market Cap: JP¥109.0b

BML Valuation

Is 4694 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4694 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4694 (¥2746) is trading below our estimate of fair value (¥8415.71)

Significantly Below Fair Value: 4694 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4694?

Other financial metrics that can be useful for relative valuation.

4694 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA2.6x
PEG Ratio35.6x

Price to Earnings Ratio vs Peers

How does 4694's PE Ratio compare to its peers?

The above table shows the PE ratio for 4694 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.3x
9158 CUC
15.3x7.1%JP¥58.1b
7840 France Bed HoldingsLtd
13.6xn/aJP¥43.5b
6099 Elan
18.7x23.8%JP¥48.1b
6078 Value HRLtd
53.7xn/aJP¥46.8b
4694 BML
18x0.5%JP¥109.0b

Price-To-Earnings vs Peers: 4694 is good value based on its Price-To-Earnings Ratio (18x) compared to the peer average (25.3x).

Price to Earnings Ratio vs Industry

How does 4694's PE Ratio compare vs other companies in the JP Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a8.7%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a8.7%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4694 is expensive based on its Price-To-Earnings Ratio (18x) compared to the JP Healthcare industry average (15.8x).

Price to Earnings Ratio vs Fair Ratio

What is 4694's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4694 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18x
Fair PE Ratio14.8x

Price-To-Earnings vs Fair Ratio: 4694 is expensive based on its Price-To-Earnings Ratio (18x) compared to the estimated Fair Price-To-Earnings Ratio (14.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4694 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥2,746.00
JP¥3,000.00
+9.2%
3.3%JP¥3,100.00JP¥2,900.00n/a2
Nov ’25JP¥2,792.00
JP¥3,000.00
+7.4%
3.3%JP¥3,100.00JP¥2,900.00n/a2
Oct ’25JP¥2,664.00
JP¥3,000.00
+12.6%
3.3%JP¥3,100.00JP¥2,900.00n/a2
Sep ’25JP¥2,743.00
JP¥3,000.00
+9.4%
3.3%JP¥3,100.00JP¥2,900.00n/a2
Aug ’25JP¥2,950.00
JP¥3,000.00
+1.7%
3.3%JP¥3,100.00JP¥2,900.00n/a2
Jul ’25JP¥2,869.00
JP¥3,000.00
+4.6%
3.3%JP¥3,100.00JP¥2,900.00n/a2
Jun ’25JP¥2,800.00
JP¥3,000.00
+7.1%
3.3%JP¥3,100.00JP¥2,900.00n/a2
May ’25JP¥2,908.00
JP¥3,033.33
+4.3%
6.2%JP¥3,300.00JP¥2,900.00n/a3
Apr ’25JP¥2,951.00
JP¥3,033.33
+2.8%
6.2%JP¥3,300.00JP¥2,900.00n/a3
Mar ’25JP¥2,831.00
JP¥3,033.33
+7.1%
6.2%JP¥3,300.00JP¥2,900.00n/a3
Feb ’25JP¥2,890.00
JP¥3,233.33
+11.9%
7.7%JP¥3,500.00JP¥2,900.00n/a3
Jan ’25JP¥3,000.00
JP¥3,233.33
+7.8%
7.7%JP¥3,500.00JP¥2,900.00n/a3
Dec ’24JP¥2,937.00
JP¥3,275.00
+11.5%
7.0%JP¥3,500.00JP¥2,900.00n/a4
Nov ’24JP¥2,874.00
JP¥3,275.00
+14.0%
7.0%JP¥3,500.00JP¥2,900.00JP¥2,792.004
Oct ’24JP¥2,796.00
JP¥3,475.00
+24.3%
4.3%JP¥3,700.00JP¥3,300.00JP¥2,664.004
Sep ’24JP¥2,935.00
JP¥3,525.00
+20.1%
4.2%JP¥3,700.00JP¥3,300.00JP¥2,743.004
Aug ’24JP¥3,000.00
JP¥3,800.00
+26.7%
12.8%JP¥4,600.00JP¥3,300.00JP¥2,950.004
Jul ’24JP¥2,895.00
JP¥3,800.00
+31.3%
12.8%JP¥4,600.00JP¥3,300.00JP¥2,869.004
Jun ’24JP¥3,055.00
JP¥3,840.00
+25.7%
12.1%JP¥4,600.00JP¥3,300.00JP¥2,800.005
May ’24JP¥3,075.00
JP¥3,840.00
+24.9%
12.1%JP¥4,600.00JP¥3,300.00JP¥2,908.005
Apr ’24JP¥3,085.00
JP¥3,975.00
+28.8%
10.6%JP¥4,600.00JP¥3,500.00JP¥2,951.004
Mar ’24JP¥3,140.00
JP¥4,025.00
+28.2%
10.7%JP¥4,500.00JP¥3,500.00JP¥2,831.004
Feb ’24JP¥3,210.00
JP¥4,350.00
+35.5%
10.6%JP¥5,000.00JP¥3,700.00JP¥2,890.004
Jan ’24JP¥3,355.00
JP¥4,350.00
+29.7%
10.6%JP¥5,000.00JP¥3,700.00JP¥3,000.004
Dec ’23JP¥3,500.00
JP¥4,268.00
+21.9%
12.6%JP¥5,000.00JP¥3,640.00JP¥2,937.005
Nov ’23JP¥3,365.00
JP¥4,268.00
+26.8%
12.6%JP¥5,000.00JP¥3,640.00JP¥2,874.005

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y